Clario, a healthcare research and technology company that delivers the leading endpoint technology solutions for clinical trials, has announced the acquisition of the technology company ArtiQ. This acquisition expands the power of artificial intelligence (AI) in Clario’s respiratory solutions portfolio and enhances the company’s ability to further leverage and develop innovative uses of AI across its service lines. Clario’s respiratory devices will integrate seamlessly with ArtiQ’s AI models to provide instant feedback on test quality, delivering faster, more reliable data for sponsors and yielding a better patient experience. The addition of ArtiQ, coupled with Clario’s recent acquisition of Inofab Health, expands Clario’s leadership position in supporting respiratory clinical trials and broadens the existing AI capability which encompasses over 50 proprietary AI/ML algorithms.

Latham & Watkins LLP represented Clario in the transaction with a corporate deal team led by New York partner David Beller, with associates Marc Klepner, Jordan Wampler, and Jeff Hannan. Latham also represented Clario in its acquisition of Inofab Health in November 2023.~~